Related Experiment Video
Updated: Jan 19, 2026
Glucagon-like Receptor Agonists
Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Katherine A Lyseng-Williamson1
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. DEcorrespondence@springer.com.
Abstract:
The article Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features, written by KA Lyseng-Williamson, was originally published Online First without open access. After publication in volume 39, issue 8, pages 805-819, Springer Healthcare IME requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by an independent educational grant from Novo Nordisk A/S . The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
04:26Streptozocin Treatment: A Zebrafish Model of Type 1 Diabetes Mellitus
06:46A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Diabetes Mellitus: Type 2 and Gestational
05:18A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
03:17Static Strength Training Method for Type 2 Diabetic Mice

